达格列净对2型糖尿病合并既往心肌梗死患者的心血管结局影响
DECLARE-TIMI 58 随机对照试验的预设亚组分析,纳入 3584 例既往心肌梗死的 2 型糖尿病患者。达格列净使主要不良心血管事件(MACE)相对风险降低 16%、绝对风险降低 2.6%,心血管死亡/心衰住院绝对风险降低 1.9%。
要点
- 既往心梗的2型糖尿病患者使用达格列净可降低MACE风险(HR 0.84)。
- 无既往心梗者MACE无获益(HR 1.00),交互作用绝对风险差异P=0.048。
- 心血管死亡/心衰住院相对风险降幅相似,但既往心梗者绝对风险降幅更大。
核心结论
- 2型糖尿病合并既往心肌梗死患者MACE及心血管死亡/心衰住院风险高,达格列净可稳健降低这两种复合终点风险。
主要发现
- 既往心梗患者(n=3584)中,达格列净组MACE发生率为15.2%,安慰剂组为17.8%(HR 0.84,95%CI 0.72-0.99,P=0.039),相对风险降低16%,绝对风险降低2.6%。
- 无既往心梗患者中MACE发生率为7.1% vs 7.1%(HR 1.00,95%CI 0.88-1.13,P=0.97);相对差异交互作用P=0.11,绝对风险差异交互作用P=0.048。
- 已确诊动脉粥样硬化性心血管疾病但无心肌梗死病史者,MACE发生率为12.6% vs 12.8%(HR 0.98,95%CI 0.81-1.19)。
- 距末次急性事件2年内MACE获益似乎更大(交互作用趋势P=0.007)。
- 心血管死亡/心衰住院:既往心梗患者8.6% vs 10.5%(HR 0.81,95%CI 0.65-1.00,P=0.046),绝对风险降低1.9%;无既往心梗患者3.9% vs 4.5%(HR 0.85,95%CI 0.72-1.00,P=0.055),绝对风险降低0.6%;相对差异交互作用P=0.69,绝对风险差异交互作用P=0.010。
临床怎么用
- 对2型糖尿病合并既往心肌梗死患者,可考虑使用达格列净以降低MACE及心血管死亡/心衰住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium glucose transporter-2 inhibitors reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus and a history of atherosclerotic cardiovascular disease. Because of their baseline risk, patients with previous myocardial infarction (MI) may derive even greater benefit from sodium glucose transporter-2 inhibitor therapy. METHODS: DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) randomized 17 160 patients with type 2 diabetes mellitus and either established atherosclerotic cardiovascular disease (n=6974) or multiple risk factors (n=10 186) to dapagliflozin versus placebo. The 2 primary end points were composite of MACE (cardiovascular death, MI, or ischemic stroke) and the composite of cardiovascular death or hospitalization for heart failure. Those with previous MI (n=3584) made up a prespecified subgroup of interest. RESULTS: In patients with previous MI (n=3584), dapagliflozin reduced the relative risk of MACE by 16% and the absolute risk by 2.6% (15.2% versus 17.8%; hazard ratio [HR], 0.84; 95% CI, 0.72-0.99; P=0.039), whereas there was no effect in patients without previous MI (7.1% versus 7.1%; HR, 1.00; 95% CI, 0.88-1.13; P=0.97; P for interaction for relative difference=0.11; P for interaction for absolute risk difference=0.048), including in patients with established atherosclerotic cardiovascular disease but no history of MI (12.6% versus 12.8%; HR, 0.98; 95% CI, 0.81-1.19). There seemed to be a greater benefit for MACE within 2 years after the last acute event ( P for interaction trend=0.007). The relative risk reductions in cardiovascular death/hospitalization for heart failure were more similar, but the absolute risk reductions tended to be greater: 1.9% (8.6% versus 10.5%; HR, 0.81; 95% CI, 0.65-1.00; P=0.046) and 0.6% (3.9% versus 4.5%; HR, 0.85; 95% CI, 0.72-1.00; P=0.055) in patients with and without previous MI, respectively ( P interaction for relative difference=0.69; P interaction for absolute risk difference=0.010). CONCLUSIONS: Patients with type 2 diabetes mellitus and previous MI are at high risk of MACE and cardiovascular death/hospitalization for heart failure. Dapagliflozin appears to robustly reduce the risk of both composite outcomes in these patients. Future studies should aim to confirm the large clinical benefits with sodium glucose transporter-2 inhibitors we observed in patients with previous MI. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01730534.
引用
- Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019. PMID: 30882239. doi:10.1161/CIRCULATIONAHA.119.039996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。